CHARLGATE
Finvasia Group, which operates multiple brands in the FinTech industry today announced that it acquired Cyprus-based financial services company, Fxview. FINVASIA Group has acquired 100% stake in the company for an undisclosed sum.
Fxview is a leading financial services and CFD broker that services clients in over 25 countries and is registered with over 6 different regulatory bodies across Europe. Over last six months, Fxview has hosted over 2 million unique users on its website and is gaining popularity swiftly across the EU, Asia, LATAM and Africa region. The company provides clients a comprehensive trading experience by offering low commissions, thin spreads, multiple platforms & trading tools and a clutter-free trading environment.
Commenting on the acquisition, Sarvjeet Virk, Managing Director of Finvasia Group said, “We’re delighted to add Fxview to our portfolio. Europe remains a key strategic priority for our business. Fxview’s acquisition gives us a significant presence in the European market, complementing our already well-established operations in United Kingdom."
“Since we started, our goal has been to provide our clients with the best possible forex trading resources and experience which is backed by state of the art technology. Finvasia is a global leader in the Fintech space and we believe this acquisition by Finvasia Group is the best way for Fxview to continue to fulfil that mission," said Daniela Egli, Executive Director of Charlgate Ltd.
With offices in India, UK, Cyprus, and Australia, Finvasia Group owns multiple brands in financial services, fintech, blockchain, real-estate, healthcare and technology sectors.
About Fxview
Fxview is a brand owned and operated by Charlgate Ltd with its headquarters in Limassol Cyprus. Charlgate Ltd operates under the European Markets in Financial Instruments Directive (MiFid) and is regulated by CySec under license 367/18 since 2018 and is a Member of the Investor Compensation Fund (ICF).
Charlgate Ltd is also registered with the UK Financial Conduct Authority – FCA ( 850138), the German Federal Financial Supervisory Authority – BaFin ( 157125), the French Autorité de Contrôle Prudentiel et de Résolution – ACPR ( 85051), the Italian Commissione Nazionale per le Società e la Borsa – CONSOB ( 5151), the Spanish Comisión Nacional de Mercado de Valores – CNVM ( 4892), the Norway Finanstilsynet – ( FT00118545).
Know more: https://fxview.com/
About FINVASIA Group
FINVASIA is a multi-disciplinary, multinational organisation that invests in technology-oriented business and products. It is registered with a gamut of regulatory bodies across the world in various capacities. Finvasia (along with its subsidiaries and sister concerns) is registered with SEC, USA (152771 ), Reserve Bank of India as an NBFC, National Stock Exchange of India as Professional Clearing member(M51912), Bombay Stock Exchange(4043), Multi Commodity Exchange of India(55135) and NCDEX as Trading Member(01259), Association of Mutual Funds of India(103331) and CDSL as Depository Participant(12084300).
Know more: https://finvasia.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005638/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom